SMRxT

What SMRxT does

SMRxT is a private health technology company founded in 2010 and headquartered in New York, NY, with an engineering and software development office in Overland Park, Kansas. The company develops Nomi, a real-time medication adherence system that captures granular data on how patients take their medications and converts that data into actionable information for clinical interventions. Nomi's architecture combines a cellular-connected smart device—powered through a strategic partnership with Verizon—with ingestible sensors that verify medication ingestion at the moment of intake. The system requires no application setup, Bluetooth, or Wi-Fi from the patient, differentiating it from app-based adherence tools.

The company's business model is B2B enterprise sales to hospitals and health plans, with the Nomi device fulfilled at the point of prescription and revenue generated through a combination of hardware device sales and recurring monitoring/data services. Pricing is not publicly disclosed, and no consumer-facing or self-serve channel exists; distribution is handled through enterprise field sales. The end user is the specialty pharmacy patient taking complex medication regimens, while the contracting buyer is the healthcare provider or payer that captures the downstream cost savings.

SMRxT addresses a market problem estimated at $300 billion annually in the total cost of medication non-adherence, including $100 billion from avoidable hospitalizations, nursing home admissions, and premature deaths. The company has raised approximately $5.26 million across three disclosed funding events between 2010 and 2018, with KCRise Fund the only named participant. SMRxT operates as a private, founder-controlled company with co-founders Victor Chu and Stephan Valter, and CEO Michael J. Huffer. The team size of 11-50 and the absence of disclosed international operations, additional products, or recent funding rounds indicate a focused but narrow operating footprint.

Name

SMRxT

Legal name

SMRxT INC

Website

https://smrxt.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

SMRxT is a private health technology company that sells Nomi, a cellular-connected medication adherence device with ingestible sensors, to hospitals and health plans on a hardware-plus-subscription basis to reduce costs from prescription non-adherence.

Ownership category

akta.pro rank

Product category

Medication Adherence Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)

akta.pro secondary industries

Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Medication Adherence, Reminders & Patient Support (HLACAKAF)

Keywords

• Medication adherence monitoring
• Remote patient monitoring devices
• Connected health hardware
• Ingestible sensor technology
• Clinical adherence analytics

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Nomi Device and Monitoring Services: Hardware device sales combined with ongoing monitoring and data services. The system captures medication adherence data and translates it into actionable information for healthcare providers and health plans, enabling patient interventions and helping avoid preventable costs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

SMRxT designs and sells the Nomi medication adherence system, a cellular-connected smart device integrated with ingestible sensors that automatically captures how patients take their medication in real time. The device transmits adherence data over Verizon's cellular network without requiring any app setup, Bluetooth, or Wi-Fi from the patient, and converts that data into actionable information used by hospitals and health plans for patient interventions and engagement.

Product overview

SMRxT offers a single unified product called Nomi — a real-time medication adherence system. Nomi captures medication-taking data and translates it into actionable information for patient interventions and engagement. The device operates automatically once a prescription is filled, requiring no application setup, Bluetooth, or Wi-Fi connectivity, and impacts patient behavior toward better health while helping hospitals and health plans avoid preventable costs.

Differentiator

Problem solved

Functional benefit

Brands

• Nomi: Real-time medication adherence system that accurately captures data to reveal how patients take medication. Translates data into actionable information for patient interventions and engagement.

Products and services

• Nomi Medication Adherence System Real-time medication adherence technology combining a cellular-connected smart device with ingestible sensors. The device is provided to patients once a prescription is filled, requires no app setup, Bluetooth, or Wi-Fi connectivity, and automatically captures adherence data that is translated into actionable information for patient interventions and engagement by hospitals and health plans.

Quantifiable outcome

• $300 billion annual cost of non-adherence can be addressed through improved adherence
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• VerizoncoreTechnology or IntegrationSMRxT is an official Verizon Partner. Through this strategic partnership, SMRxT's Nomi technology is certified and powered on the nation's largest cellular provider. This enables real-time data transmission from the medication adherence devices without requiring Wi-Fi or Bluetooth connectivity from patients.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• AdhereTech: AdhereTech builds connected smart pill bottles that capture real-time medication adherence data, operating in the same prescription-fulfillment distribution model and B2B enterprise channel as SMRxT's Nomi.
• etectRx: etectRx develops an ingestible sensor platform (ID-Cap) that transmits medication-taking events, matching SMRxT's ingestible-sensor approach for real-time adherence monitoring.
• Medisafe: Medisafe is a medication adherence platform combining patient-facing reminders and provider analytics, overlapping SMRxT's adherence-data value proposition sold to health plans and pharma.
• AiCure: AiCure uses AI-driven visual confirmation and sensor data to confirm medication ingestion in clinical trials and commercial settings, competing for the same enterprise adherence budgets SMRxT targets.

Broad incumbents

• Propeller Health: Propeller Health's connected inhaler platform is a category-defining connected therapeutic adherence solution now part of a large respiratory franchise, establishing the broader connected-drug-delivery category in which SMRxT competes.
• Proteus Digital Health (now Recare): Proteus pioneered ingestible-sensor adherence tech with FDA-cleared offerings; its restructure/rebrand reshaped the category and set the competitive benchmark SMRxT must differentiate against.
• Care4Today (Janssen/Johnson & Johnson): Janssen's Care4Today is a pharma-sponsored medication adherence program, representing the kind of manufacturer-backed incumbent payer offering SMRxT must displace in enterprise deals.

Emerging players

• Hero Health: Hero Health offers a connected in-home medication dispenser with adherence tracking, targeting the same chronic-disease, senior and specialty-adherence use cases SMRxT addresses from the prescription-fulfillment side.
• MedMinder: MedMinder provides connected pill dispensers and pharmacy services for adherence among seniors and polypharmacy patients, competing for the same payer and provider ROI dollars SMRxT pitches.

Others

• Verily (Alphabet): Verily's health platforms include connected-care and adherence-adjacent programs as part of a broader digital health portfolio, making it an adjacent incumbent whose capabilities could compete or partner with SMRxT.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SMRxT